Table 1. Characteristics of the 56 Patients in the Study and Immunotherapiesa.
| Characteristic | Patients |
|---|---|
| Age, median (range), y | 67 (25-87) |
| Male | 31 (55) |
| ECOG performance status | |
| 0 | 31 (55) |
| 1 | 22 (40) |
| 2 | 3 (5) |
| ECOG stage | |
| IIIc | 3 (5) |
| IV | 53 (95) |
| BRAF variant | |
| Yes | 11 (20) |
| No | 45 (80) |
| Presence of brain metastasis | 7 (13) |
| Lactate dehydrogenase level elevation | 8 (17)b |
| Therapy before ipilimumab (n = 54) | |
| 0 | 27 (50) |
| 1 | 19 (35) |
| 2 | 8 (15) |
| Ipilimumab treatment | |
| Cycles, median (range), No. | 3 (1-6) |
| Dose | |
| 3 mg/kg | 50 (89) |
| 10 mg/kg | 2 (4) |
| Other | 4 (7) |
| Anti–PD-1 treatment | |
| Cycles, median (range), No. | 12 (1-35) |
| Anti–PD-1 treatment | |
| Nivolumab (2 mg/kg) | 28 (50) |
| Pembrolizumab (3 mg/kg) | 28 (50) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-1, programmed cell death 1.
a
Data are presented as No. (%) of patients unless otherwise indicated.
b
Data were missing for 9 patients.